Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Aliskiren (Rasilez®) is not recommended for use within NHS Wales for the treatment of essential hypertension. The clinical and cost effectiveness data presented was insufficient for AWMSG to recommend its use. |
||
|
||
Medicine details |
||
| Medicine name | aliskiren (Rasilez®) | |
| Formulation | film-coated tablet | |
| Reference number | 18 | |
| Indication | Treatment of essential hypertension |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Full | |
| Status | Not recommended | |
| Advice number | 0409 | |
| NMG meeting date | 20/05/2009 | |
| AWMSG meeting date | 24/06/2009 | |
| Ratification by Welsh Government | 22/07/2009 | |
| Date of issue | 04/08/2009 | |